NAUT
Nautilus
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 1
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About NAUT
Nautilus Biotechnology, Inc.
A company pioneering a single-molecule protein analysis platform for quantifying the proteome
Biological Technology
Invalid Date
08/07/2020
NASDAQ Stock Exchange
155
12-31
Common stock
2701 Eastlake Avenue East Seattle, Washington, 98102
--
Nautilus Biotechnology, Inc., is a Delaware corporation. They are a development-stage life sciences company dedicated to creating platform technologies for quantifying and unlocking the complexity of the human proteome. Their mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advances in human health and medicine. They argue that incremental advances in existing technologies are not enough and that bold scientific leaps are needed to revolutionize proteomics and revolutionize precision medicine. Their vision is to integrate their breakthrough innovations in computer science, engineering and biochemistry to develop and commercialize proteomics analysis technologies with extremely high sensitivity and scale. To achieve this, they built a prototype of a single-molecule instrument, their proteomics analysis system, which will be further developed to provide the speed, simplicity, accuracy and versatility they believe are necessary to establish a new gold standard in the field.
Company Financials
EPS
NAUT has released its 2024 Q4 earnings. EPS was reported at -0.14, versus the expected -0.16, beating expectations. The chart below visualizes how NAUT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
